Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2023’, provides an overview of the Hemophilia A (Factor VIII Deficiency) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Hemophilia A (Factor VIII Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hemophilia A (Factor VIII Deficiency) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Hemophilia A (Factor VIII Deficiency)
- The report reviews pipeline therapeutics for Hemophilia A (Factor VIII Deficiency) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hemophilia A (Factor VIII Deficiency) therapeutics and enlists all their major and minor projects
- The report assesses Hemophilia A (Factor VIII Deficiency) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hemophilia A (Factor VIII Deficiency)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hemophilia A (Factor VIII Deficiency)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hemophilia A (Factor VIII Deficiency) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
AlphaMab Co LtdAlveron Pharma
Amarna Therapeutics BV
Anyuan Pharmaceutical Technology (Shanghai) Co Ltd
ASC Therapeutics Inc
Ascension Healthcare Plc
Atomwise Inc
Band Therapeutics LLC
Baudax Bio Inc
Baylor College of Medicine
Beijing Neoletix Biological Technology Co Ltd
Beijing Northland Biotech Co Ltd
Beijing Tiantan Biological Products Co Ltd
Belief Biomed Inc
Biocad
BioMarin Pharmaceutical Inc
Biotest AG
BloodCenter of Wisconsin
CANbridge Life Sciences Ltd
Casebia Therapeutics LLP
CellGenTech Inc
Centessa Pharmaceuticals Plc
Centre for Stem Cell Research
Chameleon Biosciences Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chugai Pharmaceutical Co Ltd
Daiichi Sankyo Co Ltd
Dnarx LLC
EpiVax Inc
Equilibra Bioscience LLC
Exegenesis Bio Inc
Expression Therapeutics Inc
G&P Bioscience Co Ltd
GC Biopharma Corp
GeneOne Life Science Inc
Generation Bio Co
GeneVentiv Therapeutics Inc
Hebei Da'an Pharmaceutical Co Ltd
ID Pharma Co Ltd
Idogen AB
Innovare R & D SA De CV
Intas Pharmaceuticals Ltd
Intellia Therapeutics Inc
Kaifeng Pharmaceutical (Group) Co Ltd
Kymab Ltd
LambdaGen Therapeutics
LFB SA
MediciNova Inc
Metagenomi Inc
NovalGen Ltd
Novo Nordisk AS
Octapharma AG
OPKO Health Inc
Pangen Biotech Inc
Pfizer Inc
Pharming Group NV
Poseida Therapeutics Inc
ProFactor Pharma Ltd
Rani Therapeutics LLC
Sanofi
Seattle Children’s Research Institute
Shandong Taibang Biological Products Co Ltd
Shanghai BDgene Therapeutics Co Ltd
Shenzhen Geno-Immune Medical Institute
Sichuan Yuanda Shuyang Pharmaceutical Co Ltd
Sichuan Zhishan Weixin Biotechnology Co Ltd
Sigilon Therapeutics Inc
Sino Biopharmaceutical Ltd
SinoCelltech Group Ltd
SK Plasma Co Ltd
Spark Therapeutics Inc
Staidson BioPharma Inc
State University of New York at Buffalo
Suzhou Huayi Liangjian Biotechnology Co Ltd
Suzhou Ribo Life Sciences Co Ltd
Symvivo Inc
Takeda Pharmaceutical Co Ltd
TiumBio Co Ltd
Ultragenyx Pharmaceutical Inc
University of Florida
Worg Pharmaceuticals Hangzhou Co Ltd
Zhengzhou Gensciences Inc